Setor de Oftalmologia (SEOFT), Hospital Geral de Fortaleza, Fortaleza, Brazil.
Úvea, Universidade Estadual de Campinas (UNICAMP)Setor de Oftalmologia, Departamento de Retina, Vítreo e , São Paulo, Brazil.
Ocul Immunol Inflamm. 2023 Aug;31(6):1134-1140. doi: 10.1080/09273948.2022.2093756. Epub 2022 Aug 1.
Vogt-Koyanagi-Harada (VKH) syndrome is an autoimmune, multisystemic disease characterized by severe bilateral granulomatous posterior, which can occur due to viral infection or vaccination. We report four cases that had a likely association between VKH disease and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Two patients had VKH symptoms within 1 and 2 weeks after receiving the ChAdOx1 nCoV-19 vaccine. One patient presented with VKH symptoms 5 days after receiving the BNT162b2 vaccine, and one patient had symptoms within 4 weeks after receiving the CoronaVac vaccine. Early diagnosis and treatment of VKH disease are essential for the visual prognosis of this aggressive disease. Further in-depth studies are necessary to investigate this likely association to enable ophthalmologists to identify new assumed correlations between the diseases described in this study.
Vogt-Koyanagi-Harada(VKH)综合征是一种自身免疫性、多系统疾病,其特征为严重的双侧肉芽肿性后部病变,可由病毒感染或接种疫苗引起。我们报告了四例可能与 VKH 疾病和严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)疫苗接种相关的病例。两例患者在接种 ChAdOx1 nCoV-19 疫苗后 1 至 2 周出现 VKH 症状。一例患者在接种 BNT162b2 疫苗后 5 天出现 VKH 症状,一例患者在接种 CoronaVac 疫苗后 4 周内出现症状。早期诊断和治疗 VKH 疾病对于这种侵袭性疾病的视觉预后至关重要。需要进一步深入研究以探讨这种可能的关联,使眼科医生能够识别本研究中描述的疾病之间的新假定相关性。